Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light

The latest drug development news and highlights from our US FDA Performance Tracker. 

Keeping Track Feature image

In scoring an approval for a Parkinson's disease indication, Kyowa Hakko Kirin Co. Ltd.'s Nourianz (istradefylline) became the ninth novel drug cleared by the Center for Drug Evaluation and Research this August, tying the modern monthly record that it previously set a year ago in August 2018.

CDER has now approved 26 novel agents so far in 2019.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>